Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapid Oral Switch in Infectious Endocarditis (ROSIE)
2025-524484-20-00Phase 4Authorised
- Sponsor
- UZ Leuven
- Start
- Feb 2026
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of amoxicillin, amoxicillin + clavulanate, cefazolin, flucloxacillin, trimethoprim + sulfamethoxazole and 7 more in endocarditis (IE), sponsored by UZ Leuven. Primary endpoint: Composite clinical success at 6 months. Planned start Feb 2026; status: authorised.
02
Drugs
amoxicillinamoxicillin + clavulanatecefazolinflucloxacillintrimethoprim + sulfamethoxazole
03
Conditions
endocarditis (IE)
Beyond the preview
Go deeper on 2025-524484-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524484-20-00.